Table 1

LCN2 protein expression by various clinico-pathological variables and molecular markers among 256 endometrial cancers
Variable LCN2 SI 0N (%) LCN2 SI 1-9N (%) P-valuea
Histologic type Endometrioid 126 (55%) 103 (45%) 0.001
Non- endometrioid 5 (19%) 22 (81%)
Histologic grade Grade 1 and 2 89 (56%) 71 (44%) 0.066
Grade 3 42 (44%) 54 (56%)
Nuclear grade Grade 1 and 2 101 (59%) 71 (41%) 0.001
Grade 3 30 (36%) 54 (64%)
Solid growth <50% 104 (56%) 82 (44%) 0.013
≥50% 27 (39%) 43 (61%)
Mitosesb Low 103 (54%) 89 (46%) NS
High 28 (44%) 36 (56%)
FIGO stagec,d I/II 109 (53%) 97 (47%) NS
III/IV 22 (45%) 27 (55%)
ERe,f Negative 25 (40%) 38 (60%) 0.028
Positive 103 (56%) 82 (44%)
PRg,h Negative 28 (38%) 46 (62%) 0.006
Positive 98 (57%) 74 (43%)
EZH2i,j Weak 121 (56%) 94 (44%) <0.001
Strong 10 (24%) 31 (76%)
HER2k,l Weak 115 (54%) 100 (46%) 0.084
Strong 11 (37%) 19 (63%)
VEGF-Am,n Weak 114 (55%) 94 (45%) 0.021
Strong 17 (36%) 30 (64%)

aP-value from χ2 test. Mitoses: bmedian used as cut-off point. FIGO stage: caccording to 1998 criteria, dmissing data in one case. ER: emissing data in 8 cases, flower quartile used as cut-off point. PR: gmissing data in 8 cases, hlower quartile used as cut-off point. EZH2:imissing data in 10 cases, jupper quartile used as cut-off point HER2: kmissing data in 11 cases, lmedian used as cut-off point and VEGF-A:mmissing data in one case, nupper quartile used as cut-off point.

Mannelqvist et al.

Mannelqvist et al. BMC Cancer 2012 12:169   doi:10.1186/1471-2407-12-169

Open Data